B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
ADC
BCMA
BITE
CAR T-cell
antibody–drug conjugate
bifunctional antibodies
chimeric antigen receptor T-cell therapy
monoclonal antibody
multiple myeloma
myeloma
relapsed refractory multiple myeloma
Journal
Therapeutic advances in hematology
ISSN: 2040-6207
Titre abrégé: Ther Adv Hematol
Pays: England
ID NLM: 101549589
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
09
2020
accepted:
04
01
2021
entrez:
2
4
2021
pubmed:
3
4
2021
medline:
3
4
2021
Statut:
epublish
Résumé
Outcomes of patients with multiple myeloma (MM) who become refractory to standard therapies are particularly poor and novel agents are greatly needed to improve outcomes in such patients. B-cell maturation antigen (BCMA) has become an important therapeutic target in MM with three modalities of treatment in development including antibody-drug conjugates (ADCs), bispecific T-cell engagers (BITEs), and chimeric antigen receptor (CAR) T-cell therapies. Early clinical trials of anti-BCMA immunotherapeutics have demonstrated extremely promising results in heavily pretreated patients with relapsed/refractory MM (RRMM). Recently, belantamab mafodotin was the first anti-BCMA therapy to obtain approval in relapsed/refractory MM. This review summarizes the most updated efficacy and safety data from clinical studies of BCMA-targeted therapies with a focus on ADCs and BITEs. Additionally, important differences among the BCMA-targeted treatment modalities and their clinical implications are discussed.
Identifiants
pubmed: 33796236
doi: 10.1177/2040620721989585
pii: 10.1177_2040620721989585
pmc: PMC7970693
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2040620721989585Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: Larysa Sanchez: none Alexandra Dardac: none Deepu Madduri: Advisory Board/Consulting: Celgene, Janssen, BMS, Takeda, Legend, GSK, Kinevant, Foundation Medicine Shambavi Richard: none Joshua Richter: Speakers bureau: Janssen, Celgene, Adaptive Biotechnologies Consulting/Advisory Board: Celgene, Janssen, BMS, Karyopharm, Antengene, Sanofi, X4 Pharmaceuticals, Oncopeptides, Adaptive Biotechnologies, Secura Bio, Astra Zeneca.
Références
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Leukemia. 2020 Apr;34(4):985-1005
pubmed: 32055000
J Clin Oncol. 2020 Mar 10;38(8):775-783
pubmed: 31895611
Drugs. 2017 Sep;77(14):1603-1610
pubmed: 28819740
Clin Cancer Res. 2018 Jul 15;24(14):3242-3246
pubmed: 29476018
Pharmacol Ther. 2019 Sep;201:103-119
pubmed: 31028837
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Lancet Oncol. 2020 Feb;21(2):207-221
pubmed: 31859245
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Lancet. 2020 Jul 18;396(10245):186-197
pubmed: 32682484
J Hematol Oncol. 2020 Sep 17;13(1):125
pubmed: 32943087
Blood. 2014 May 15;123(20):3128-38
pubmed: 24569262
Br J Haematol. 2012 Sep;158(6):727-38
pubmed: 22804669
J Hematol Oncol. 2020 Dec 3;13(1):164
pubmed: 33272302
Haematologica. 2017 Apr;102(4):785-795
pubmed: 28034989
Blood. 2016 Jun 23;127(25):3225-36
pubmed: 27127303
Haematologica. 2020 May;105(5):e261-e263
pubmed: 32107339
Leukemia. 2019 Sep;33(9):2266-2275
pubmed: 30858549
Cancer Discov. 2018 Aug;8(8):924-934
pubmed: 30012854
Lancet. 2019 Dec 7;394(10214):2096-2107
pubmed: 31735560
Leukemia. 2019 Mar;33(3):766-771
pubmed: 30315237
Blood. 2004 Jan 15;103(2):689-94
pubmed: 14512299
Ophthalmol Ther. 2020 Dec;9(4):889-911
pubmed: 32712806
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
Leukemia. 2021 Jan;35(1):255-258
pubmed: 32317775
Clin Cancer Res. 2019 Sep 15;25(18):5441-5448
pubmed: 30979742
Clin Cancer Res. 2016 Jul 1;22(13):3383-97
pubmed: 26960399
Blood Res. 2017 Dec;52(4):243-253
pubmed: 29333400
Blood Cancer J. 2019 Mar 20;9(4):37
pubmed: 30894515
Cancers (Basel). 2020 Jun 05;12(6):
pubmed: 32516895